基本信息 产品详情 公司简介 推荐产品
网站主页 REGN4461 REGN4461
  • (Mibavademab)Biosimilar-Reference-Antibody-GS40434
  • (Mibavademab)Biosimilar-Reference-Antibody-GS40434
  • (Mibavademab)Biosimilar-Reference-Antibody-GS40434

1/3

(Mibavademab)Biosimilar-Reference-Antibody-GS40434 新品

Mibavademab
300 100μg 起订
湖北 更新日期:2026-03-06

武汉迈思生物科技有限公司

VIP1年
联系人:王爽
手机:18007167883 拨打
邮箱:Service@mabnus.com

产品详情:

中文名称:
REGN4461
英文名称:
Mibavademab
CAS号:
2305770-44-7
品牌:
Mabnus
产地:
武汉
保存条件:
store at -20°C or -80°C. Avoid repeated freeze.
纯度规格:
>95% by SDS-PAGE
重组:
应用:
ELISA;FC;Functional Assays;IF
种属反应性:
Human
宿主:
Genetically human
偶联物:
靶点:
LEPR/CD295/OBR
免疫原:
LEPR/CD295/OBR
亚型:
IgG4 - kappa
验证方法:
(Mibavademab)Biosimilar Reference Antibody(GS40434) on SDS-PAGE under non-reducing (NR) and reducing (R) condition.

货号:GS40434

Mibavademab (also known as REGN-4461) is an investigational, fully human monoclonal antibody that targets leptin receptor (LEPR), a key receptor involved in the regulation of energy homeostasis and metabolism. By binding to LEPR, mibavademab functions as a leptin receptor agonist, mimicking the action of the hormone leptin. This activation is intended to restore leptin signaling in individuals with congenital leptin receptor deficiency or other forms of leptin receptor dysfunction, thereby reducing hyperphagia (extreme hunger), improving metabolic parameters, and promoting weight loss. It is being developed as a potential therapy for severe, early-onset obesity due to LEPR deficiency and related metabolic disorders.


Mibavademab;

公司简介

武汉迈思生物科技有限公司立足于解决行业内功能活性蛋白表达及高亲和力、高灵敏度抗体开发难的痛点,依托自建的两大核心技术平台:哺乳动物细胞蛋白表达平台和单个B细胞抗体开发平台,竭诚为广大科研机构、高等院校、IVD企业、医药企业等提供一站式蛋白表达及抗体开发相关产品和技术服务。

成立日期 (5年)
注册资本 壹佰伍拾万圆人民币
员工人数 10-50人
年营业额 ¥ 100万以内
经营模式 试剂
主营行业 抗体,蛋白组学

REGN4461相关厂家报价

内容声明
拨打电话 立即询价